HALOHalozyme Therapeutics, Inc.

$110.41+42% 1Y

What is the market doing?

Mixed

No clear lean: in an uptrend, but heavily shorted (+12% of shares).

1 good, 1 to watch, 1 neutral
TrendUptrendderived · Oct 9, 2026

In an uptrend, above its rising 50- and 200-day averages. Price is +41% vs its 200-day average.

Insider conviction−$22.1M (90 days to Oct 8, 2026)SEC EDGAR · Oct 8, 2026

Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).

Short interest12% of sharesFINRA · Sep 15, 2026

Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

1-year returnbetter than 79% of the market
vs 200-day avgtop 6% of the market

Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.

How HALO is trading

Halozyme Therapeutics, Inc. is +42% over the past year while the S&P 500 is +18%: 24 points ahead of the market.

+42%

1-year return · S&P 500 +18%

vs 200-day average
+41%

vs 200-day average · a clear uptrend

RSI (14)
48

RSI (14) · neutral

Below its 52-week high
4.2%

Below its 52-week high

Sep 18, 2024$42.57 – $115.27 · dashed line: 200-day averageOct 9, 2026
Details›
Last close2026-10-09
$110.41
1 monthS&P 500 +2.7%
+3.2%
1 yearS&P 500 +18%
+42%
5 yearsS&P 500 +88%
+167%
vs 50-day average$105.16
+5.0%
52-week high
$115.27
52-week low
$61.63
Annualised volatility
44%
Calendar-year price return
YearReturn
2026 (year to date)+64%
2025+41%
2024+29%
2023−35%
2022+42%
2021−5.9%
2020+141%
2019+21%
2018−28%
2017+105%
Average return by calendar month, 2016–2026
MonthYearsPositiveAverage
Jan106 of 10+3.2%
Feb107 of 10+3.5%
Mar104 of 10−2.7%
Apr105 of 10+2.3%
May105 of 10−0.85%
Jun107 of 10+6.4%
Jul118 of 11+7.1%
Aug117 of 11+5.1%
Sep114 of 11+1.6%
Oct114 of 11−5.0%
Nov108 of 10+14%
Dec103 of 10−0.77%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.